Compounds, compositions and methods for treating ocular conditions

• US 8,614,200 B2
• Filed: 07/21/2010
• Issued: 12/24/2013
• Est. Priority Date: 07/21/2009
• Status: Active Grant

• Current Assignee: Emergent BioDefense Operations Lansing, LLC (Emergent Biosolutions Inc.)
• Original Assignee: Chimerix Incorporated
• Inventors: Painter, George R., Almond, Merrick R.
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US13/386,604
• Publication Number:
  US 20120165295A1
• Time in Patent Office: 1,252 Days
• Field of Search: 514/86
• US Class Current: 514/86
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: C07F 9/6512 having the nitrogen atoms in positions 1 and 3
• CPC Class Codes: C07F 9/65742 non-condensed with carbocyclic rings or heterocyclic rings or ring systems
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered.

Claims

1. An ophthalmic composition comprising:

an ophthalmically acceptable carrier and a compound in an amount effective to treat a viral infection, wherein said compound is

2. The composition of claim 1, wherein the compound is

3. The composition of claim 1, wherein the compound is

4. The composition of claim 1, wherein the composition comprises a topically acceptable carrier.

5. The composition of claim 1, wherein the ophthalmic composition is in the form selected from the group consisting of an aqueous solution, a non-aqueous solution, a suspension, a solution/suspension, a gel, a cream, an ointment, and an emulsion.

6. The composition of claim 1, wherein the composition further comprises at least one excipient selected from the group consisting of stabilizer, a penetrating enhancer, a pH adjusting agent, an antimicrobial preservative, a lubricant, a viscosifier, and a wetting agent.

7. The composition of claim 1, further comprises purified water, carbomer, trolamine, propylparaben, methylparaben, propylene glycol, and glycerin.

8. The composition of claim 1, wherein the amount of the compound is in the range of about 0.001% to 30% by weight.

9. The composition of claim 8, wherein the amount of the compound is about 5% by weight.

10. A method of treating a viral infection of the eye comprising administering an ophthalmic composition to a subject, wherein the composition comprises an ophthalmically acceptable carrier and

11. The method of claim 10, wherein the compound is

12. The method of claim 10, wherein the compound is

13. The method of claim 10, wherein said viral infection is selected from the group consisting of influenza, herpes simplex virus (HSV), human herpes virus, cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella zoster virus (VZV), orthopox virus, variola major and minor, vaccinia, cowpox, camelpox, monkeypox, papilloma virus, adenovirus, polyoma virus including JC virus, BK virus, SV40 and a combination thereof.

14. The method of claim 13, wherein said viral infection is selected from the groups consisting of cytomegalovirus, varicella zoster virus, adenovirus, herpes simplex virus and Epstein-Barr virus.

15. The method of claim 10, wherein the composition is topically administered to the eye.

16. The method of claim 15, wherein the composition is topically administered to the cornea and/or conjunctiva of the subject.

17. The method of claim 10, wherein the composition is intraocularly administered.

18. The method of claim 17, wherein the composition is administered by intraocular injection.

19. The method of claim 18, wherein the composition is administered by retrobulbar, intravitreal, intraretinal or subconjunctival injection.

20. The method of claim 10, wherein the viral infection is due to a double stranded DNA (dsDNA) virus.